Levetiracetam

Generic Name: Levetiracetam

Brand Names: Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₄N_₂O_₂

CAS Number: 102767-28-2

Unique Ingredient Identifier: 44YRR34555

Background: Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential to produce, or be subject to, pharmacokinetic interactions - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.

Indication: Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.

Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.

Associated Conditions: Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures

Associated Therapies: -

Clinical Trials

Pregabalin Versus Levetiracetam In Partial Seizures

Phase 3

Completed

Conditions: Partial Seizures

Interventions: Drug: pregabalin
Drug: levetiracetam

First Posted Date: 2007-10-01

Last Posted Date: 2021-01-28

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 509

Registration Number: NCT00537238

Locations: 🇻🇪
Pfizer Investigational Site, Caracas, Miranda, Venezuela

Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Levetiracetam

First Posted Date: 2007-09-26

Last Posted Date: 2011-08-31

Lead Sponsor: UCB Pharma

Target Recruit Count: 33

Registration Number: NCT00535392

Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

Not Applicable

Completed

Conditions: Premenstrual Dysphoric Disorder

Interventions: Drug: Levetiracetam

First Posted Date: 2007-08-20

Last Posted Date: 2007-08-20

Lead Sponsor: Berkshire Health Systems

Target Recruit Count: 7

Registration Number: NCT00518570

Locations: 🇺🇸
Berkshire Medical Center, Clinical Trials Program, Department of Psychiatry, Pittsfield, Massachusetts, United States

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Levetiracetam

First Posted Date: 2007-07-25

Last Posted Date: 2015-07-15

Lead Sponsor: UCB Pharma SA

Target Recruit Count: 19

Registration Number: NCT00505934

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

Phase 2

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mycophenolate mofetil
Drug: Sirolimus
Procedure: Allogeneic bone marrow transplant
Radiation: Total body irradiation - 200
Drug: Levetiracetam
Biological: Anti-thymocyte globulin
Radiation: Total body irradiation - 400